H J van der Linde1, B Van Deuren, Y Somers, B Loenders, R Towart, D J Gallacher. 1. Center of Excellence for Cardiovascular Safety Research and Mechanistic Pharmacology, Johnson & Johnson Pharmaceutical Research and Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium. hvdlinde@its.jnj.com
Abstract
BACKGROUND AND PURPOSE: In cardiovascular pharmacology, electrical and mechanical events can be distinguished, and the phrase 'electro-mechanical window' (EMw) describes the temporal difference between these events. We studied whether changes in EMw have potential predictive value for the occurrence of arrhythmias in fentanyl/etomidate-anaesthetized beagle (FEAB) dogs. EXPERIMENTAL APPROACH: The EMw was calculated as differences between the QT interval and QLVP(end) in FEAB dogs during atrial pacing, treatment with isoprenaline or atropine, body temperature changes and induction of Torsade de Pointes (TdP) in an LQT1 model. KEY RESULTS: The electrical systole (QT interval) was shorter than the duration of the mechanical event (QLVP(end) ), providing a positive EMw. Atrial pacing, atropine or body temperature changes had no major effects on EMw, despite large changes in QT duration. However, β-adrenoceptor stimulation (with isoprenaline) decreased the EMw (from 90 to 5 ms) and in combination with HMR1556, a blocker of the slowly activating potassium current (I(Ks) ), induced a large negative EMw (-109ms) and TdP. Prevention of TdP by atenolol or verapamil was associated with a less negative EMw (-23 to -16ms). Mexiletine, a poorly effective long QT treatment, did not affect the EMw or prevent TdP induction. CONCLUSIONS AND IMPLICATIONS: The EMw is a marker, other than QT prolongation, of TdP risk in the FEAB model. Therefore, we suggest examining the EMw as a risk marker in cardiovascular safety studies and as a potential biomarker to improve clinical management of long QT syndrome patients, especially in patients with borderline QT prolongation.
BACKGROUND AND PURPOSE: In cardiovascular pharmacology, electrical and mechanical events can be distinguished, and the phrase 'electro-mechanical window' (EMw) describes the temporal difference between these events. We studied whether changes in EMw have potential predictive value for the occurrence of arrhythmias in fentanyl/etomidate-anaesthetized beagle (FEAB) dogs. EXPERIMENTAL APPROACH: The EMw was calculated as differences between the QT interval and QLVP(end) in FEAB dogs during atrial pacing, treatment with isoprenaline or atropine, body temperature changes and induction of Torsade de Pointes (TdP) in an LQT1 model. KEY RESULTS: The electrical systole (QT interval) was shorter than the duration of the mechanical event (QLVP(end) ), providing a positive EMw. Atrial pacing, atropine or body temperature changes had no major effects on EMw, despite large changes in QT duration. However, β-adrenoceptor stimulation (with isoprenaline) decreased the EMw (from 90 to 5 ms) and in combination with HMR1556, a blocker of the slowly activating potassium current (I(Ks) ), induced a large negative EMw (-109ms) and TdP. Prevention of TdP by atenolol or verapamil was associated with a less negative EMw (-23 to -16ms). Mexiletine, a poorly effective long QT treatment, did not affect the EMw or prevent TdP induction. CONCLUSIONS AND IMPLICATIONS: The EMw is a marker, other than QT prolongation, of TdP risk in the FEAB model. Therefore, we suggest examining the EMw as a risk marker in cardiovascular safety studies and as a potential biomarker to improve clinical management of long QT syndromepatients, especially in patients with borderline QT prolongation.
Authors: Anthony R Magnano; Steve Holleran; Rajasekhar Ramakrishnan; James A Reiffel; Daniel M Bloomfield Journal: J Am Coll Cardiol Date: 2002-06-05 Impact factor: 24.094
Authors: Hanno L Tan; Abdennasser Bardai; Wataru Shimizu; Arthur J Moss; Eric Schulze-Bahr; Takashi Noda; Arthur A M Wilde Journal: Circulation Date: 2006-11-06 Impact factor: 29.690
Authors: Bruno Van Deuren; Karel Van Ammel; Yves Somers; Frank Cools; Roel Straetemans; Henk J van der Linde; David J Gallacher Journal: J Pharmacol Toxicol Methods Date: 2009-05-05 Impact factor: 1.950
Authors: David J Gallacher; André Van de Water; Henk van der Linde; An N Hermans; Hua Rong Lu; Rob Towart; Paul G A Volders Journal: Cardiovasc Res Date: 2007-06-29 Impact factor: 10.787
Authors: Kristina Hermann Haugaa; Thor Edvardsen; Trond P Leren; Jon Michael Gran; Otto A Smiseth; Jan P Amlie Journal: Eur Heart J Date: 2008-10-21 Impact factor: 29.983
Authors: T R G Stams; V J A Bourgonje; H D M Beekman; M Schoenmakers; R van der Nagel; P Oosterhoff; J M van Opstal; M A Vos Journal: Br J Pharmacol Date: 2014-02 Impact factor: 8.739
Authors: Pierre Morissette; Sebastian Polak; Anne Chain; Jin Zhai; John P Imredy; Mary Jo Wildey; Jeffrey Travis; Kevin Fitzgerald; Patrick Fanelli; Elisa Passini; Blanca Rodriguez; Frederick Sannajust; Christopher Regan Journal: Toxicol Appl Pharmacol Date: 2020-01-23 Impact factor: 4.219